Cargando…
A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against S...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998260/ https://www.ncbi.nlm.nih.gov/pubmed/36894570 http://dx.doi.org/10.1038/s41541-023-00624-y |
_version_ | 1784903436941131776 |
---|---|
author | Meron-Sudai, Shiri Asato, Valeria Adler, Amos Bialik, Anya Goren, Sophy Ariel-Cohen, Ortal Reizis, Arava Mulard, Laurence A. Phalipon, Armelle Cohen, Dani |
author_facet | Meron-Sudai, Shiri Asato, Valeria Adler, Amos Bialik, Anya Goren, Sophy Ariel-Cohen, Ortal Reizis, Arava Mulard, Laurence A. Phalipon, Armelle Cohen, Dani |
author_sort | Meron-Sudai, Shiri |
collection | PubMed |
description | Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate. |
format | Online Article Text |
id | pubmed-9998260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-99982602023-03-10 A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults Meron-Sudai, Shiri Asato, Valeria Adler, Amos Bialik, Anya Goren, Sophy Ariel-Cohen, Ortal Reizis, Arava Mulard, Laurence A. Phalipon, Armelle Cohen, Dani NPJ Vaccines Article Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate. Nature Publishing Group UK 2023-03-10 /pmc/articles/PMC9998260/ /pubmed/36894570 http://dx.doi.org/10.1038/s41541-023-00624-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Meron-Sudai, Shiri Asato, Valeria Adler, Amos Bialik, Anya Goren, Sophy Ariel-Cohen, Ortal Reizis, Arava Mulard, Laurence A. Phalipon, Armelle Cohen, Dani A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
title | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
title_full | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
title_fullStr | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
title_full_unstemmed | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
title_short | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
title_sort | shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998260/ https://www.ncbi.nlm.nih.gov/pubmed/36894570 http://dx.doi.org/10.1038/s41541-023-00624-y |
work_keys_str_mv | AT meronsudaishiri ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT asatovaleria ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT adleramos ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT bialikanya ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT gorensophy ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT arielcohenortal ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT reizisarava ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT mulardlaurencea ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT phaliponarmelle ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT cohendani ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT meronsudaishiri shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT asatovaleria shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT adleramos shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT bialikanya shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT gorensophy shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT arielcohenortal shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT reizisarava shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT mulardlaurencea shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT phaliponarmelle shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT cohendani shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults |